Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC increased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 22.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,288 shares of the medical research company's stock after purchasing an additional 10,270 shares during the period. Janus Henderson Group PLC owned 0.11% of Charles River Laboratories International worth $10,390,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its position in Charles River Laboratories International by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company's stock valued at $1,136,938,000 after purchasing an additional 60,497 shares in the last quarter. Wellington Management Group LLP raised its stake in Charles River Laboratories International by 9.0% in the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after acquiring an additional 335,658 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Charles River Laboratories International by 2.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock worth $330,231,000 after buying an additional 47,221 shares during the period. Geode Capital Management LLC raised its holdings in shares of Charles River Laboratories International by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company's stock worth $227,042,000 after purchasing an additional 14,787 shares during the last quarter. Finally, Ariel Investments LLC lifted its holdings in shares of Charles River Laboratories International by 18.9% in the 4th quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company's stock valued at $197,029,000 after buying an additional 169,640 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL traded up $2.11 on Tuesday, hitting $143.49. The company's stock had a trading volume of 956,394 shares, compared to its average volume of 981,879. The company has a 50-day simple moving average of $134.84 and a 200 day simple moving average of $164.49. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15. The company has a market capitalization of $7.05 billion, a PE ratio of 956.60, a PEG ratio of 4.54 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same quarter in the previous year, the firm posted $2.27 EPS. The firm's revenue was down 2.7% on a year-over-year basis. Sell-side analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on CRL. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. JPMorgan Chase & Co. dropped their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. Redburn Atlantic raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective on the stock in a report on Monday, March 3rd. Morgan Stanley lowered their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. Finally, Mizuho lowered their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a report on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $172.31.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president now owns 19,513 shares of the company's stock, valued at $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Birgit Girshick acquired 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. This represents a 2.83% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders sold 5,040 shares of company stock valued at $807,407. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).